Congratulations to Prof. Ed Tate who has been appointed to the Scientific Advisory Board of Samsara Therapeutics Inc.

Prof. Ed Tate has been appointed to the Scientific Advisory Board of Samsara Therapeutics Inc., a discovery-stage biotech with a world-leading screening platform for inducers of autophagy and a growing pipeline of small molecule neurodegeneration and rare disease therapeutics.

Alongside the other SAB members, Ed will help the company advance several series of novel compounds into development for Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and certain rare genetic conditions, with a particular focus on target identification and validation.

More information can be found here.